EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis,and Cellular Characterization ofa New Class of IPMK Kinase Inhibitors

Pratima Chapagain, Raymond D. Blind, Desmarini Desmarini, Xiaodong Wang, Lucia E. Rameh, Dilipkumar Uredi, Yubai Zhou, Julianne T. Djordjevic, Michael A. Stashko, Hundaol Huluka

Carolina Digital Repository (University of North Carolina at Chapel Hill) · 15.07.2026

DOI: 10.17615/2dqm-hp60 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Carolina Digital Repository (University of North Carolina at Chapel Hill), erschienen am 15.07.2026. Verfasst von Pratima Chapagain und 9 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The kinase activity of human inositol phosphate multikinase (IPMK) is required for the synthesis of higher-order inositol phosphate signaling molecules, regulation of gene expression, and control of the cell cycle. Here, we report a novel series of highly potent IPMK inhibitors. The first-generation IPMK inhibitor 1 (UNC7437) decreased cellular proliferation and tritiated inositol phosphate levels in metabolically labeled human U251-MG glioblastoma cells. It also impacted the transcriptome of these cells, selectively regulating 993 genes enriched in cancer, epithelial-to-mesenchymal transition (EMT), and inflammatory and viral infection pathways, consistent with anticancer growth activity. Extensive optimization of 1 led to 14 (UNC9750) with improved pharmacokinetic properties. Compound 14 inhibited cellular accumulation of InsP5, the direct product of IPMK kinase activity, while having no effect on either InsP6 or InsP7 levels. These studies suggest that rapid chemical inhibition of IPMK induces a novel InsP5 metabolic signature, providing new biological insights into inositol phosphate metabolism and signaling.

Schlagwörter

inositol pentakisphosphateinositol phosphate metabolisminositol phosphate signalingglioblastomaU251 cellsanticancer activityepithelial-mesenchymal transitiontranscriptomepharmacokinetic optimizationkinase inhibitors

Zitieren

APA

Chapagain, P., Blind, R. D., Desmarini, D., Wang, X., Rameh, L. E., Uredi, D., Zhou, Y., Djordjevic, J. T., Stashko, M. A., & Huluka, H. (2026). Design, Synthesis,and Cellular Characterization ofa New Class of IPMK Kinase Inhibitors. Carolina Digital Repository (University of North Carolina at Chapel Hill). https://doi.org/10.17615/2dqm-hp60

Vancouver

Chapagain P, Blind RD, Desmarini D, Wang X, Rameh LE, Uredi D, et al. Design, Synthesis,and Cellular Characterization ofa New Class of IPMK Kinase Inhibitors. Carolina Digital Repository (University of North Carolina at Chapel Hill). 2026. doi:10.17615/2dqm-hp60

BibTeX
@article{Chapagain2026,
  author = {Chapagain, Pratima and Blind, Raymond D. and Desmarini, Desmarini and Wang, Xiaodong and Rameh, Lucia E. and Uredi, Dilipkumar and Zhou, Yubai and Djordjevic, Julianne T. and Stashko, Michael A. and Huluka, Hundaol},
  title = {Design, Synthesis,and Cellular Characterization ofa New Class of IPMK Kinase Inhibitors},
  journal = {Carolina Digital Repository (University of North Carolina at Chapel Hill)},
  year = {2026},
  doi = {10.17615/2dqm-hp60}
}
Kostenlos starten →